Biology of renal tumour cancer stem cells applied in medicine

Wspolczesna Onkologia

Volumn 1A, Issue , 2015, Pages A44-A51

  Matak, Damian ^a,b   Szymanski, Lukasz ^a,c   Szczylik, Cezary ^a   Sledziewski, Rafal ^a   Lian, Fei ^d   Bartnik, Ewa ^c,e   Sobocinska, Anna ^a,c   Czarnecka, Anna M ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c UNIVERSITY OF WARSAW   (Poland)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF BIOCHEMISTRY AND BIOPHYSICS   (Poland)

Author keywords

Cancer stem cells; Renal cancer; Tumour initiating cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; CARBONATE DEHYDRATASE IX; CD133 ANTIGEN; CELL SURFACE MARKER; CHEMOKINE RECEPTOR CXCR4; ENDOGLIN; HERMES ANTIGEN; NERVE CELL ADHESION MOLECULE;

CANCER PROGNOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL FUNCTION; HUMAN; KIDNEY CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84981240563     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2014.47128     Document Type: Review

References (71)

1. NCI. Definition of renal cell cancer. http://www.cancer.gov/dictionary?cdrid=44988
2. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol 2010; 7: 245-57.
3. Buczek M, Escudier B, Bartnik E, Szczylik C, Czarnecka A. Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient's bed to molecular mechanisms. Biochim Biophys Acta 2014; 1845: 31-41.
4. Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett 2014; 343: 156-60.
5. Diamond E, Riches J, Faltas B, Tagawa ST, Nanus DM. Immunologics and chemotherapeutics for renal cell carcinoma. Semin Intervent Radiol 2014; 31: 91-7.
6. Shiozawa Y, Nie B, Pienta KJ, Morgan TM, Taichman RS. Cancer stem cells and their role in metastasis. Pharmacol Ther 2013; 138: 285-93.
7. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 2007; 6: 1684-90.
8. Bansal N, Banerjee D. Tumor initiating cells. Curr Pharm Biotechnol 2009; 10: 192-6.
9. Warrington K, Hillarby MC, Li C, Letarte M, Kumar S. Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res 2005; 25: 1851-64.
10. Gougos A, St Jacques S, Greaves A, et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 1992; 4: 83-92.
11. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, Gougos A, Letarte M, Bernabeu C. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992; 22: 393-7.
12. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J 2000; 14: 55-64.
13. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001; 2: 82-91.
14. Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D. Identification of novel Prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci 2004; 117: 4301-11.
15. Mizrak D, Brittan M, Alison M. CD133: molecule of the moment. J Pathol 2008; 214: 3-9.
16. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-12.
17. Bussolati B, Collino F, Camussi G. CD133+ cells as a therapeutic target for kidney diseases. Expert Opin Ther Targets 2012; 16: 157-65.
18. Florek M, Bauer N, Janich P, et al. Prominin-2 is a cholesterol-binding protein associated with apical and basolateral plasmalemmal protrusions in polarized epithelial cells and released into urine. Cell Tissue Res 2007; 328: 31-47.
19. Bourseau-Guilmain E, Griveau A, Benoit J-P, Garcion E. The importance of the stem cell marker prominin-1/CD133 in the uptake of transferrin and in iron metabolism in human colon cancer Caco-2 cells. PloS One 2011; 6: e25515.
20. Neuzil J, Stantic M, Zobalova R, et al. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name? Biochem Biophys Res Commun 2007; 355: 855-9.
21. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G. Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 2008; 22: 3696-705.
22. Bruno S, Bussolati B, Grange C, Collino F, Graziano ME, Ferrando U, Camussi G. CD133+ renal progenitor cells contribute to tumor angiogenesis. Am J Pathol 2006; 169: 2223-35.
23. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009; 18: 17-25.
24. Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006; 107: 2162-9.
25. Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, Nolta JA. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004; 104: 1648-55.
26. Marcato P, Dean CA, Pan D, et al. Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells 2011; 29: 32-45.
27. Armstrong L, Stojkovic M, Dimmick I, Ahmad S, Stojkovic P, Hole N, Lako M. Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells 2004; 22: 1142-51.
28. Pearce DJ, Taussig D, Simpson C, Allen K, Rohatiner AZ, Lister TA, Bonnet D. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells 2005; 23: 752-60.
29. Skommer J, Wlodkowic D, Pelkonen J. CXCR4 expression during tumour cell death. Leuk Res 2007; 31: 1155-6.
30. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002; 13: 143-54.
31. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62: 1832-7.
32. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410: 50-6.
33. Greubern EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukemia to solid tumors. Nat Rev Cancer 2013; 13: 559-71.
34. Ueland J, Yuan A, Marlier A, Gallagher AR, Karihaloo A. A novel role for the chemokine receptor Cxcr4 in kidney morphogenesis: an in vitro study. Dev Dyn 2009; 238: 1083-91.
35. Ruoslahti E. The Walter Herbert Lecture. Control of cell motility and tumour invasion by extracellular matrix interactions. Br J Cancer 1992; 66: 239-42.
36. Tawfik OW, Kramer B, Shideler B, Danley M, Kimler BF, Holzbeierlein J. Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med 2007; 131: 261-7.
37. Rioux-Leclercq N, Epstein JI, Bansard JY, et al. Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. Hum Pathol 2001; 32: 1209-15.
38. Nouwen EJ, Dauwe S, van der Biest I, De Broe ME. Stage-and segment-specific expression of cell-adhesion molecules N-CAM, A-CAM, and L-CAM in the kidney. Kidney Int 1993; 44: 147-58.
39. Abbate M, Brown D, Bonventre JV. Expression of NCAM recapitulates tubulogenic development in kidneys recovering from acute ischemia. Am J Physiol 1999; 277 (3 Pt 2): F454-63.
40. Garin-Chesa P, Fellinger EJ, Huvos AG, Beresford HR, Melamed MR, Triche TJ, Rettig WJ. Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence. Am J Pathol 1991; 139: 275-86.
41. Daniel L, Bouvier C, Chetaille B, et al. Neural cell adhesion molecule expression in renal cell carcinomas: relation to metastatic behavior. Hum Pathol 2003; 34: 528-32.
42. Rink M, Chun FKH, Robinson B, et al. Tissue-based molecular markers for renal cell carcinoma. Minerva Urol Nefrol 2011; 63: 293-308.
43. Minardi D, Lucarini G, Mazzucchelli R, et al. Prognostic role of Fuhrman grade and vascular endothelial growth factor in pt1a clear cell carcinoma in partial nephrectomy specimens. J Urol 2005; 174: 1208-12.
44. Dubinski W, Gabril M, Iakovlev VV, et al. Assessment of the prognostic significance of endoglin (CD105) in clear cell renal cell carcinoma using automated image analysis. Hum Pathol 2012; 43: 1037-43.
45. D'Alterio C, Cindolo L, Portella L, et al. Differential role of CD133 and CXCR4 in renal cell carcinoma. Cell Cycle 2010; 9: 4492-500.
46. Kim K, Ihm H, Ro JY, Cho YM. High-level expression of stem cell marker CD133 in clear cell renal cell carcinoma with favorable prognosis. Oncol Lett 2011; 2: 1095-100.
47. Costa WHd, Rocha RM, Cunha IW, Fonseca FP, Guimaraes GC, Zequi Sde C. CD133 immunohistochemical expression predicts progression and cancer-related death in renal cell carcinoma. World J Urol 2012; 30: 553-8.
48. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev 2011; 7: 292-306.
49. Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY. Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 2008; 6: 1146-53.
50. Jiang F, Qiu Q, Khanna A, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7: 330-8.
51. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67.
52. Kim MP, Fleming JB, Wang H, et al. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 2011; 6: e20636.
53. van den Hoogen C, van der Horst G, Cheung H, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010; 70: 5163-73.
54. Ozbek E, Calik G, Otunctemur A, Aliskan T, Cakir S, Dursun M, Somay A. Stem cell markers aldehyde dehydrogenase type 1 and nestin expressions in renal cell cancer. Arch Ital Urol Androl 2012; 84: 7-11.
55. Ueda K, Ogasawara S, Akiba J, et al. Aldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell line. PLoS One 2013; 8: e75463.
56. Abourbih S, Sircar K, Tanguay S, Kassouf W, Aprikian A, Mansure J, Brimo F. Aldehyde dehydrogenase 1 expression in primary and metastatic renal cell carcinoma: an immunohistochemistry study. World J Surg Oncol 2013; 11: 298.
57. Ottaiano A. Finding markers for cancer stem cells in renal cell carcinoma: looking beyond CD133. Cell Cycle 2010; 9: 4431.
58. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, Melamed J, Semenza GL. Stromal cell-derived factor-1alpha and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 2005; 65: 6178-88.
59. Wang L, Chen W, Gao L, Yang Q, Liu B, Wu Z, Wang Y, Sun Y. High expression of CXCR4, CXCR7 and SDF-1 predicts poor survival in renal cell carcinoma. World J Surg Oncol 2012; 10: 212.
60. Li G, Badin G, Zhao A, Gentil-Perret A, Tostain J, Peoc'h M, Gigante M. Prognostic value of CXCR4 expression in patients with clear cell renal cell carcinoma. Histol Histopathol 2013; 28: 1217-22.
61. Noroozinia F, Fahmideh AN, Yekta Z, Rouhrazi H, Rasmi Y. Expression of CD44 and P53 in renal cell carcinoma: association with tumor subtypes. Saudi J Kidney Dis Transpl 2014; 25: 79-84.
62. Moskvina LV, Andreeva II, Frank GA, Zavalishina LE, Petrov AN, Mal'kov PG. Prognostic value of the expression of adhesion molecules for non-clear-cell variants of renal cell carcinoma. Ark Patol 2013; 75: 3-8.
63. Zhang Y, Sun B, Zhao X, Liu Z, Wang X, Yao X, Dong X, Chi J. Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma. J Surg Oncol 2013; 108: 414-9.
64. Cirović SL, Cegar BS, Vjestica JM, et al. Expression of neural cell adhesion molecule in renal cell carcinoma. Acta Chir Iugosl 2012; 59: 39-44.
65. Tostain J, Li G, Gentil-Perret A, Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer 2010; 46: 3141-8.
66. Bui MHT, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11.
67. Phuoc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, Hirose Y. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep 2008; 20: 525-30.
68. Zhang BY, Thompson RH, Lohse CM, Dronca RS, Cheville JC, Kwon ED, Leibovich BC. Carbonic anhydrase IX (CAIX) is not an independent predictor of outcome in patients with clear cell renal cell carcinoma (ccRCC) after long-term follow-up. BJU Int 2013; 111: 1046-53.
69. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-92.
70. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014; 46: 225-33.
71. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012; 4: 127ps110.